

Final programme



# 8<sup>th</sup> ESPT CONGRESS

5-8 NOVEMBER 2025

Rotterdam



## ESPT

European Society of Pharmacogenomics and Personalised Therapy  
A Scientific Society for Individualised Medicine

Under the auspices of



International Federation  
of Clinical Chemistry  
and Laboratory Medicine



EUROPEAN FEDERATION OF CLINICAL CHEMISTRY  
AND LABORATORY MEDICINE



# COMMITTEES

## ESPT Congress Organisation

Ron van Schaik (NL)  
Mikko Niemi (FI)  
Erika Cecchin (IT)  
Tiffany Morris (GB)

## ESPT Scientific Advisory Board

Magnus Ingelman-  
Sundberg (SE)  
Urs Meyer (CH)  
Matthias Schwab (DE)  
Munir Pirmohamed (GB)  
Mia Wadelius (SE)  
Cristina Rodríguez-  
Antona (ES)

## ESPT Board

Mikko Niemi (FI)  
Ann Daly (GB)  
Vita Dolzan (SI)  
Sanja Stankovic (CS)  
Ron van Schaik (NL)  
Adrian Llerena (ES)  
Espen Molden (NO)  
Erika Cecchin (IT)  
Tiffany Morris (GB)

## Local Congress Organisation

Ron van Schaik  
Teun van Gelder  
Jesse Swen  
Ron Mathijssen  
Birgit Koch  
Petra Hoogland  
Maja Matic  
Marieke Coenen  
Naomi Jessurun

## Poster Committee

Ingolf Cascorbi (DE)  
Mia Wadelius (SE)  
Urs Meyer (CH)  
Cristina Rodríguez-Antona  
(ES)

# WELCOME LETTER



**Prof. Dr. Ron van Schaik**  
Chair Local Organization Committee



**Prof. Dr. Mikko Niemi**  
ESPT President

Dear colleagues,

The 8<sup>th</sup> International Congress of the European Society for Pharmacogenomics and Personalised Therapy (#ESPT2025) has started! A big welcome to all of you to the exciting city of Rotterdam, and to the ESPT2025 meeting venue “De Doelen”.

The #ESPT2025 congress will again bring together leading international scientists, healthcare professionals, pharmacists, laboratory specialists, clinicians, students, GPs, regulators and industry representatives to exchange the latest knowledge on pharmacogenomics and personalised therapy during this great 4-day event. This 8th congress follows successful events in the previous years (Copenhagen 2023, Belgrade 2021 (held in 2022), Seville 2019, Catania 2017, Budapest 2015, Lisbon 2013 and Bled 2011). With over 40 world class plenary speakers, 160 posters and 400 attendees from more than 30 different countries. Together with the latest information presented by 20 exhibitors, we hope you will find this meeting valuable for progressing the field of pharmacogenetics!

We are proud to announce that the Dean of Erasmus MC as well as the IFCC President will open the event, which is held under the auspices of IFCC and EFLM. Congress topics include current initiatives and future directions on pharmacogenomics

and personalised medicine, covering clinical implementation, psychiatry, oncology, liquid biopsy, cardiology, diabetes, solid organ transplantation, pediatrics, regulatory aspects, genotyping technologies, decision support tools and national society initiatives. In addition, there are pre-congress symposia, educational workshops, four national society mini-symposia societies and a discussion forum on Saturday morning, following up on the success of this in the Copenhagen meeting. The organization is very grateful to the city of Rotterdam to host the ESPT2025 opening reception on Wednesday at City Hall. And for those who registered, a highlight (literally) will be the conference dinner at the Euromast on Thursday!

We hope that #ESPT2025 will provide you with the opportunity to exchange experiences in basic, clinical and translational aspects of pharmacogenomics, create opportunities to explore new ideas and start new collaborations while catching up with friends and colleagues. And, in addition, allow you to discover the vibrant city of Rotterdam!

Enjoy your conference!  
On behalf of the entire  
ESPT2025 Organizing Committee

# SPEAKERS

**Akkers, Robert** - Results Laboratorium, Dordrecht, The Netherlands  
**Alix-Panabieres, Catherine** - Laboratory of Rare Human Circulating Cells, CHU de Montpellier, France  
**Ansari, Marc** - Hematology-oncology unit of the Geneva University Hospital, Switzerland  
**Becker, Alexandra** - EP PerMed, Bonn, Germany  
**Bloor, Claire** - Thermo Fisher  
**Brown, Matthew** - Gernomics England, London, UK  
**Cascorbi, Ingolf** - Institute for Experimental and Clinical Pharmacology, University Hospital Schleswig-Holstein and University of Kiel, Germany  
**Cecchin, Erika** - Experimental and Clinical Pharmacology Unit, National Cancer Institute, Aviano, Italy  
**Chandler, Scott** - Precision Safety at Roche, Switzerland  
**Cornel, Martina** - Amsterdam University Medical Centers, The Netherlands  
**Elens, Laure** - Pharmacy and Biomedical Sciences of UCLouvain in Brussels, Belgium  
**Florindi, Francesco** - Policy Officer European Commission, DG Research & Innovation  
**French, Cerissa** - Oxford Nanopore  
**Garcia-Gonzalez, Xandra** - Gregorio Marañón University Hospital in Madrid, Spain  
**Goldenberg, Oliver** - Roche  
**Gratton, Jasmine** - European Medicine Agency, Amsterdam, The Netherlands  
**Hertz, Daniel** - University of Michigan College of Pharmacy, USA  
**Hoffmann, Per** - life&brain, Bonn, Germany  
**Hosio, Antti** - Comprehensive Cancer Centre of Helsinki University Hospital, Finland  
**Hughes, Dyfrig** - Bangor University, Wales, UK  
**Ingelman-Sundberg, Magnus** - Karolinska Institutet, Stockholm, Sweden  
**Koch, Birgit** - Erasmus MC, Rotterdam, The Netherlands  
**Kulla, Noora** - Finnish Society of Clinical Pharmacology, Helsinki, Finland  
**Langhoff, Daniel** - Eurofins Genomics  
**Lebreton, Louis** - University Hospital of Bordeaux, France  
**Litonius, Kaisa** - HUS Helsinki University Hospital, Finland  
**Llerena, Adrian** - INUBE Biosanitary University Research Institute, Badajoz, Spain  
**López-Fernández, Luis Andrés** - Hospital Gregorio Marañón, Madrid, Spain  
**Maitland-van der Zee, Anke-Hilse** - UMCG in Groningen, The Netherlands  
**Mancuso, David** - Nicklaus Children's Hospital, Miami, USA  
**Manolopoulos, Vangelis** - Former Head Greek Organization of Medicines  
**Melnick, Steven** - Nicklaus Children's Hospital Biobank, Miami, USA  
**Meyer, Urs** - Biozentrum, University of Basel, Switzerland  
**Miele, Gino** - Genedrive  
**Mitropoulou, Christina** - Golden Helix Foundation, London, UK  
**Molden, Espen** - Diakonhjemmet Hospital, and University of Oslo, Norway  
**Morris, Tiffany** - Illumina  
**Müller, Daniel** - CAMH and University of Toronto, Canada  
**Muñoz-Galeano, Herna** - PGXperts GmbH, Fürth, Germany  
**Newman, William** - University of Manchester, UK  
**Niemi, Mikko** - University of Helsinki, Finland

**Ozben, Tomris** - President of the International Federation of Clinical Chemistry and Laboratory Medicine (IFCC)

**Palmer, Colin** - University of Dundee, Scotland, UK

**Pantel, Klaus** - Institute of Tumor Biology and University Medical Center Hamburg-Eppendorf, Germany

**Patrinos, George** - Hellenic Pasteur Institute in Athens and University of Patras, Greece

**Pearson, Ewan** - University of Dundee and Edinburgh, Scotland, UK

**Picard, Nicolas** - University and University Hospital, Limoges, France

**Pirmohamed, Munir** - Institute of Systems, Molecular and Integrative Biology (ISMIB), University of Liverpool, UK

**Pratt, Vicky** - Agena Biosciences, Indiana, USA

**Raymond, Laure** - Eurofins Biomnis, France

**Rodríguez-Antona, Cristina** - Instituto de Investigaciones Biomédicas Sol-Morreale (IIBM), Madrid, Spain

**Roncato, Rossana** - University of Udine, Italy

**Roozenbeek, Bob** - Erasmus MC, Rotterdam, The Netherlands

**Rosenquist, Richard** - Karolinska Institute. Karolinska University Hospital, Sweden

**Salazar, Juliana** - Sant Pau Institute of Biomedical Research, Barcelona, Spain

**Schwab, Matthias** - University of Tuebingen and the Dr Margarete Fischer-Bosch-Institute of Clinical Pharmacology, Stuttgart, Germany

**Squassina, Alessio** - University Cagliari, Italy and Dalhousie University, Halifax, Canada

**Stocco, Gabriele** - University of Trieste, Italy

**Suarez-Kurtz, Guilherme** - Brazilian National Cancer Institute and Brazilian National Pharmacogenetics Network

**Swen, Jesse** - Leiden University Medical Center, The Netherlands

**Ten Berg, Jur** - St Antonius Center for Platelet Function Studies at the St Antonius Hospital, The Netherlands

**Van den Broek, Daan** - Antoni van Leeuwenhoek Cancer Instituut, Amsterdam, The Netherlands

**van der Lee, Maaïke** - Leiden University Medical Center, The Netherlands

**Van Gelder, Teun** - Leiden University Medical Center, The Netherlands

**van Schaik, Ron** - Erasmus MC, Rotterdam, The Netherlands

**Wadelius, Mia** - University of Uppsala, Sweden

**Woodahl, Erica** - L.S. Skaggs Institute for Health Innovation (SIHI) at the University of Montana, USA

**From 07.30 REGISTRATIONS OPEN**

09:00 - 11:00 **Zaal 2 - ESPT Executive Board meeting** – Closed Meeting

09:00 - 12:00 **Zaal 5 - Apothekers/Huisartsen Symposium** (in Dutch)

09:00 - 12:00 **Zaal 8 - NVKC / CMBD Symposium** (in Dutch)

11:00 - 12:00 **Zaal 2 - ESPT GENERAL ASSEMBLY** - Closed Meeting

13:00 - 13:30 **OPENING of the CONGRESS**

**Willem Burger Zaal** - Plenary

Welcome - *Ron van Schaik* - Local Organizer

Opening - *Mikko Niemi* - ESPT President

Welcome - *Tomris Ozben* - IFCC President

Welcome - *Stefan Sleijfer* - Dean Erasmus MC - Rotterdam

13:30 - 15:20 **SESSION 01: CLINICAL IMPLEMENTATION**

**Willem Burger Zaal**

*Chairs: Ron van Schaik & Jesse Swen*

13:30 Implementation of PGx in the UK: a perspective - *Sir Munir Pirmohamed*  
(Keynote Lecture)

13:55 Large scale Pharmacogenomics and Genomics England - *Matthew Brown*

14:20 Universal clinical implementation of PGx in Spain: results of pilot study in  
public healthcare - *Adrian Llerena*

14:45 Implementaton of PGx in The Netherlands: beyond PREPARE - *Jesse Swen*

15:10 Selected Abstract: Cost Effectiveness analysis: results of the PREPARE  
study in Europe - *Christina Mitropoulos*

15:20 - 15:50 **TEA & COFFEE BREAK and POSTERS VIEWING**

15:50 - 17:15 **SESSION 02: PSYCHIATRY**

**Willem Burger Zaal**

*Chairs: Adrian Llerena & Birgit Koch*

15:50 Complementary use of PGx and TDM in antidepressive treatment -  
*Espen Molden*

16:15 Integration of PGx in psychiatry: experiences from Canada - *Daniel Mueller*

16:40 Genome-guided therapeutics in psychiatry: results from the PREPARE  
study and beyond - *George Patrinos*

17:05 Selected Abstract: Variation in CYP2D6 Influences Fluoxetine and  
Norfluoxetine Exposure in Children and Adolescents - *Poweleit Ethan*

From 17:30 **OPENING RECEPTION** at CITY HALL

From 07.30 REGISTRATIONS OPEN



08:00 - 08:45 **Willem Burger Zaal - Educational Workshop**

*Agena Bioscience & Platomics*

Towards clinical guideline and IVDR compliant pharmacogenetic testing. Implementing pharmacogenetic panel solutions for enhanced outcomes and regulatory adherence - *Maaïke van der Lee*

08:00 - 08:45 **Zaal 5 - Mini Symposium**

*Finnish Society of Clinical Pharmacology*

Clinical implementation of PGx in Finland

*Chair: Mikko Niemi*

08:00 Translating Pharmacogenetics into Clinical Practice: Insights from the First 10,000 Patients Genotyped with a 12-Gene Panel - *Kaisa Litonius*

08:15 Perceptions of the general public and healthcare professionals on pharmacogenetic testing - *Noora Kulla*

08:30 Implementing *DPYD* genotyping in Finland: impact on fluoropyrimidine exposure and safety - *Antti Hosio*

08:00 - 08:45 **Zaal 8 - Mini Symposium**

*Francophone Network of PGx (RNPGx)*

Using pangenomic data in PGx

*Chair: Nicolas Picard*

08:00 WES and PGx: technical challenges and clinical opportunities - *Laure Raymond*

08:20 Organizational and regulatory aspects - *Louis Lebreton*

09:00 - 10:40 **SESSION 03: PEDIATRICS**

**Willem Burger Zaal**

*Chairs: Marieke Coenen & Espen Molden*

09:00 Optimal busulfan exposure enhances hematopoietic stem cells transplantation outcomes in high-risk pediatric ALL -

*Marc Ansari/Vid Mlaker*

09:25 Genotype-guided asthma treatment reduces exacerbations in children – *Anke-Hilse Maitland-van der Zee*

09:50 Reducing aminoglycoside ototoxicity through MT-RNR1 testing - *William Newman*

10:15 Pharmacogenomics of anti-TNF drugs in pediatric inflammatory bowel disease. From research to clinical implementation? - *Luis Andrés López-Fernández*

10:40 - 11:10 **TEA & COFFEE BREAK and POSTERS VIEWING**



**11:10 - 13:00 SESSION 04: ONCOLOGY**

**Willem Burger Zaal**

*Chairs: Ron Mathijssen & Erika Cecchin*

- 11:10 Clinical benefit and utility of DPYD and UGT1A1 testing in gastrointestinal cancer: beyond single-gene targeted genotyping - *Erika Cecchin*
- 11:35 CYP2D6 and tamoxifen: current status - *Matthias Schwab*
- 12:00 US FDA and guidelines perspectives on DPYD testing - *Daniel Hertz*
- 12:25 New developments in Precision Oncology - *Scott Chandler*
- 12:50 Selected Abstract: Survival outcomes after UGT1A1 genotype-guided dosing of irinotecan: results of a multicentre survival analysis - *Sofia Peeters*

**13:00 - 14:30 WORKING LUNCH / POSTERS VIEWING / BOOTHS VISITS**

**14:30 - 16:20 SESSION 05: CARDIOVASCULAR**

**Willem Burger Zaal**

*Chairs: Mikko Niemi & Mia Wadelius*

- 14:30 Genetics and Precision Medicine in diabetes care - *Ewan Pearson*
- 14:55 Pharmacogenetics of statins - *Mikko Niemi*
- 15:20 CYP2C19 genotyping in patients undergoing percutaneous coronary intervention - *Jur ten Berg*
- 15:45 CYP2C19 and clopidogrel in ischemic stroke: current status - *Bob Roozenbeek*
- 16:10 Selected Abstract: Drug-drug-gene interactions in predicting cardiovascular drug-related efficacy and safety outcomes - PGx-CardioDrug Project - *Lana Ganoci*

**16:20 - 16:50 TEA & COFFEE BREAK and POSTERS VIEWING**

**16:50 - 18:15 SESSION 06: SOLID ORGAN TRANSPLANTATION**

**Willem Burger Zaal**

*Chairs: Teun van Gelder & Nicolas Picard*

- 16:50 Pharmacogenetics in solid organ transplantation: ready for implementation? - *Teun van Gelder*
- 17:15 Crosstalk between gut microbiome and immunosuppressive drugs in kidney transplantation - *Laure Elens*
- 17:40 Pharmacogenetics in kidney transplantation: from targeted analysis of immunosuppressants to the pharmacogenetic passport - *Nicolas Picard*
- 18:05 Selected Abstract: Lower Dose-Normalized Tacrolimus Exposure in CYP3A5\*6 vs.\*3 Loss-of-Function Allele Carriers: A Longitudinal Retrospective Real-World Study in Kidney Transplant Recipients - *Amar Levens*

**20.00 SOCIAL DINNER**

Location: **EUROMAST** - Address: Parkhaven 20, 3016 GM Rotterdam  
Private bus transfers from the congress venue are available, from 19:30



7 FRIDAY  
November

**From 07.30 REGISTRATIONS OPEN**

**08:00 - 08:45 Willem Burger Zaal - Educational Workshop**   
*illumina*  
Clinical Implementation of Pharmacogenomics in the Scottish NHS  
*Colin Palmer*

**08:00 - 08:45 Zaal 5 - Mini Symposium**  
*Spanish Society of Pharmacogenetics and Pharmacogenomics (SEFF)*  
Implementation of pharmacogenetics in Spain  
*Chair: Cristina Rodríguez-Antona*  
08:00 Implementation of the Pharmacogenetic testing catalog of the National Healthcare System - *Xandra García-Gonzalez*  
08:20 SEFF pharmacogenetics guidelines - *Juliana Salazar*

**08:00 - 08:45 Zaal 8 - Mini Symposium**  
*Italian Society of Pharmacology (SIF)*  
*Chair: Erika Cecchin*  
08:00 Personalized psychiatry: pharmacogenetic insights - *Alessio Squassina*  
08:15 Integrating pharmacogenetics, drug monitoring and pharmaco-vigilance for optimized and safer oral anticancer treatment - *Rossana Roncato*  
08:30 Pharmacogenomics for children: mechanistic insights from studies on extracellular vesicles - *Gabriele Stocco*

**09:00 - 10:40 SESSION 07: GLOBAL PERSPECTIVES**

**Willem Burger Zaal**

*Chairs: Ann Daly & Sanja Stankovic*

- 09:00 PGRN: fostering global awareness of pharmacogenomics - *Erica Woodahl* (PGRN President - Keynote Lecture)
- 09:25 Long read sequencing and return of results to biobank participants - *Lili Milani*
- 09:50 Bridging the Gap: understanding missing heritability in pharmacogenomics - *Magnus Ingelman-Sundberg*
- 10:15 Pharmacogenomic diversity in Latin American populations: Brazil as a model case - *Guilherme Suarez-Kurtz*

**10:40 - 11:10 TEA & COFFEE BREAK and POSTERS VIEWING**

**11:10 - 12:50 SESSION 08: LIQUID BIOPSY**

**Willem Burger Zaal**

*Chairs: Daan van den Broek & Cristina Rodríguez-Antona*

- 11:10 Liquid biopsy: current state of the art - *Klaus Pantel* (Keynote Lecture)

**SESSION 08: LIQUID BIOPSY**

- 11:35 Unraveling the biology of metastasis-competent circulating tumor cells: insights into the metastatic cascade - *Catherine Alix-Panabieres*
- 12:00 Integrated diagnostics in oncology: bridging tumor markers, liquid biopsy, multi-omics, and imaging: through clinical case studies - *Tomris Ozben*
- 12:25 Implementation of ctDNA analysis: COIN initiative - *Daan van den Broek*
- 12:50 Selected Abstract: Liquid biopsy biomarkers for personalized post-transplant care: Clinical relevance of dd-cfDNA and microRNA monitoring in liver transplantation - *Judith Julian*

13:00 - 14:15 WORKING LUNCH / POSTERS VIEWING / BOOTHS VISITS

14:15 - 15:55 **SESSION 09: POPULATION, TECHNICAL AND ETHICAL ASPECTS**

**Willem Burger Zaal**

*Chairs: Maja Matic & Ingolf Cascorbi*

- 14:15 Genomic Medicine Sweden – implementing precision medicine at national level - *Richard Rosenquist*
- 14:40 Advancing pharmacogenetics testing using long-read sequencing and ONT's adaptive sampling - *Per Hoffmann*
- 15:05 Unlocking clinical value in pharmacogenetic testing: real-life insights from the lab - *Robert Akkers*
- 15:30 Ethical aspects of PGx as secondary finding - *Martina Cornel*

15:55 - 16:25 TEA & COFFEE BREAK and POSTERS VIEWING

16:25 - 17:40 **SESSION 10: DECISION SUPPORT TOOL & ECONOMICAL ASPECTS**

**Willem Burger Zaal**

*Chairs: Maaïke van der Lee & Vita Dolzan*

- 16:25 Association for Molecular Pathology's Recommendations for clinical pharmacogenotyping allele selection - *Vicky Pratt*
- 16:50 Advancing personalized medication in primary care through digitalization and pharmacogenetics - *Herna Muñoz-Galeano*
- 17:15 Economics of pharmacogenetic-guided treatments - *Dyfrig Hughes*

17:40 **ESPT Contribution Award** - *Mikko Niemi & Ron van Schaik*

17:50 Group picture

**From 09.00 REGISTRATIONS OPEN**

**Willem Burger Zaal**

*Chairs: Birgit Koch & Mikko Niemi*

**09:00 - 09:30** One test, a life-time of impact: pre-emptive PGx testing in pediatric care - *Steve J. Melnick and David Mancuso*

**09:30** Selected Abstract: Direct comparison of Oxford Nanopore Technologies adaptive sampling with the Twist Alliance long-read hybridization panel for pharmacogenomic passport construction - *Koen Deserrano*

**09:40** POSTER AWARDS - Chair of Poster Committee

**09:50 - 11:50 DISCUSSION FORUM - How to further implement PGx?**

**Willem Burger Zaal** - *Chair: Ron van Schaik*

**1. Clinical Implementation of Pharmacogenetics across Europe**

Munir Pirmohamed (UK), Erika Cecchin (IT), Adrian Llerena (ES), Mikko Niemi (FI), Jesse Swen (NL), Mia Wadelius (SE), Lili Milani (EE), Steven Melnick (US), Laure Elens (BE)

**2. Ethical and regulatory aspects**

William Newman (UK), Martina Cornel (NL), Daniel Hertz (US), Jasmine Gratton (EMA), Vangelis Manolopoulos (Former Head Greek Organization of Medicines)

**3. Industry view on PGx developments**

Claire Bloor (Thermo Fisher), Vicky Pratt (Agena), Cerissa French (Oxford Nanopore), Gino Miele (Gene Drive), Tiffany Morris (Illumina), Daniel Langhoff (Eurofins Genomics), Oliver Goldenberg (Roche)

**4. Which are the needs on PGx research?**

Magnus Ingelman-Sundberg (SE), Ingolf Cascorbi (DE), Teun van Gelder (NL), Alexandra Becker (EP PerMed), Birgit Koch (NL), Francesco Florindi (Policy Officer European Commission, DG Research & Innovation), Erica Woodahl (PGRN President)

**11:50** Announcement ESPT2027

**12:00** END OF THE CONGRESS

**15:00 - 16:00** Studio 8 - Publiekslezing - Post conference lecture for General Public  
Farmacogenetica: uw DNA paspoort voor medicatie! *Ron van Schaik*

# CONGRESS VENUE

## DE DOELEN - Inspiring location

With over 30 rooms, de Doelen is a popular location for high-profile international events and conferences. Enriching and inspiring people by bringing them together in a hospitable environment to knowledge is one of de Doelen's spearheads.

Nationally and internationally, de Doelen wants to fulfil a mobilising, inspiring and facilitating pivotal role as a conference centre.

Address: **Kruisplein 40, 3012 CL Rotterdam**  
**30 minutes by train from Schiphol Airport**



## POSTERS

Posters are displayed at 3rd Floor.

The Poster Area will be properly indicated by sign boards.

Posters are arranged by topic and displayed on two different days:

|          |                          |               |
|----------|--------------------------|---------------|
| Thursday | 6 <sup>th</sup> November | 09:00 - 18:00 |
| Friday   | 7 <sup>th</sup> November | 09:00 - 18:00 |

Posters are numbered and must be on display ONLY on the day assigned to the author. The Organising Secretariat does not take any responsibility for posters left on display afterwards. Posters left on display after the agreed time, will NOT be stored.

To encourage discussion, poster presenters are asked to be at the assigned poster panel during the breaks.

The Poster Evaluation Committee will select two winners that will be announced on Saturday 8<sup>th</sup> November at the end of the scientific sessions.

The winning posters will be uploaded on <https://www.esptcongress.org/>

# GENERAL INFORMATION

## Dutch Accreditation



31



21



20



21



18.5



9

## Exhibition Opening Hours

The Exhibition Area is located in the Willem Burger Foyer

Wednesday 5 November  
13:00 – 17:00

Thursday 6 November  
08:00 – 18:00

Friday 7 November  
08:00 – 18.00

## Official Language

All lectures will be held in **English**.

## Badges

All registered participants, speakers and exhibitors will be given a badge, which they must mandatorily wear within the congress areas at any time.

## WI-FI Connection

Net: ESPT Congress  
Password: ESPT2025

## Certificate of Attendance

Certificates of attendance will be sent by e-mail to all registered attendees after the congress.

## Lunch and coffee break

Lunches and coffee breaks will be served at the venue, in the Auditorium Foyer only.

## Opening Ceremony

*(included in the registration fee)*

The Opening Ceremony will be held at the City Hall.

## Congress Dinner

*(not included in the registration fee)*

The Social Dinner will be held in the stunning EUROMAST on

**Thursday, November 6<sup>th</sup> at 20.00**

Tickets can be purchased till seats will be available: € 90 per person.

# POSTERS

6 THURSDAY  
November

## PSYCHIATRY

### T01

#### **Offering Publicly-Funded Pharmacogenomic Testing for Major Depressive Disorder in British Columbia, Canada: Recommendations from a Public Deliberation**

*Edwards Louisa, O'Doherty Kieran C., Bentley Colene, Austin J9 (Jehannine), Bunka Mary, Bousman Chad, Riches Linda, Ridgway Lisa, Bryan Stirling*

### T02

#### **Impact of Cytochrome P450 and NFIB genotypes on clozapine levels in smokers and nonsmokers – a retrospective naturalistic study**

*Lenk Hasan Çağın, Bråten Line Skute, Andreassen Ole A., Molden Espen*

### T03

#### **Impact of fluvoxamine co-medication on primary and toxic metabolites of clozapine in smoking and nonsmoking patients**

*Solbakk Maria, Løvsletten Smith Robert, Wollmann Birgit M., Molden Espen*

### T04

#### **Bridging pharmacogenetics and clinical practice: a personalized protocol for methadone administration**

*Recarey-Rama Sheila, Gil-Rodriguez Almudena, Gómez-Trigo Jesús, Rodríguez-Viyuela Ana, Cruz Raquel, Barral-Raña Alba, Dominguez Eduardo, Arrojo Manuel, Carracedo Angel, Maroñas Olalla*

### T05

#### **Variants in dopaminergic pathway genes and their role in the development and therapeutic response of treatment-resistant schizophrenia**

*Santos Marília Aparecida Batista dos, Selani Ana Luiza da Silva, Betarelli Beatriz Cristina, Guerra Ana Elisa Palha, Siqueira Izabelle de Faria, Mastroianni Patrícia de Carvalho, Lledó Eva María Peñas, Forgerini Marcela*

### T06

#### **Economic Effectiveness of Pharmacogenomics-Guided Prescribing for Psychiatric Disorders: A Systematic Review and Meta-Analysis**

*Mason Ellen, Ali Mohamed, Gibson David, Murray Elaine, Burns Richéal, Kelly Catriona*

## **T07**

### **Does music impact on students' psychoemotional state?**

*Kuznetsova Milena, Taran Oleksiy, Marchuk Albina, Bibichenko Viktoriia, Heydarov Husseyn, Kuznetsova Irena, Kuznetsov Kostiantyn*

## **T08**

### **The levels of plasma kynurenines increase after antidepressant treatment in depressed patients**

*Chappell Kenneth, Colle Romain, El Asmar Khalil, Fève Bruno, David Denis, Verstuyft Céline, Becquemont Laurent, Corruble Emmanuelle*

## **T09**

### **Variation in CYP2D6 Influences Fluoxetine and Norfluoxetine Exposure in Children and Adolescents**

*Poweleit Ethan A, Koertje Catherine M, Leabo Addison M, Sparks Whitney R, Robertson Gail C, Malloy Walton Lindsey E, Stancil Stephani L, Strawn Jeffrey R, Pagano Alexa L, Retke Brandon, Toren Paul, Wagner Jonathan B, Leeder J Steven, Ramsey Laura B*

## **PEDIATRICS**

## **T10**

### **Identification of germline candidate gene variants for adverse drug response screening in Indian children with acute lymphoblastic leukemia in the UK biobank**

*Gloor Yvonne, Dupanloup Isabelle, Dubashi Biswajit, Bakhshi Sameer, Ansari\* Marc, Uppugunduri\* Chakradhara Rao*

## **T11**

### **Pharmacogenomics of chemotherapy-induced toxicity in pediatric oncology patients with solid tumors: a systematic review**

*Hansson Paula, Blacker Christopher, Uvdal Hanna, Wadelius Mia, Green Henrik, Ljungman Gustaf*

## **T12**

### **Development of a predictive polygenic pharmacogenetic score for adalimumab response using exome sequencing in children with inflammatory bowel disease**

*Zapata Cobo Paula, Velloso Perceval, Salvador Martín Sara, Velasco Rodríguez Belvís Marta, Palomino Pérez Laura María, Moreno Álvarez Ana, Montraveta Montserrat, Pérez Begoña, Fobelo María José, García Romero Ruth, García Tirado Diana, Sánchez Sánchez César, Toli*

## **T13**

### **Exploratory Analysis of Pharmacogenetic Variants Affecting Individual Response to Caffeine Therapy in Apnea of Prematurity**

*Zucchet Enrique G., Solaz- García Álvaro, García-Robles Ana, Torrejón-Rodríguez Laura, Pinilla- González Alejandro, Hervás David, Herrero María José, Sáenz-González Pilar*



**T14**

**Severe Toxicity in a Breast Cancer Patient Due to the Novel DPYD Variant c.272G>T (p.Cys91Phe)**

*Krens Lisanne, Dietvorst Anne-Marie, Smit Pieter, Bosch Tessa*

**T15**

**Novel inhibitors for breast cancer resistance protein and P-glycoprotein found among drugs used in the treatment of cancer**

*Timonen Martina*

**T16**

**Survival of cancer patients with DPYD variant alleles and dose-individualized fluoropyrimidine therapy – A matched-pair analysis**

*Knikman Jonathan E., Wilting Tycho A., Lopez-Yurda Marta, Henricks Linda M., Lunenburg Carin A. T. C., de Man Femke M., Meulendijks Didier, Creemers Geert-Jan, Imholz Alexander L. T., Mathijssen Ron H. J., Portielje Johanna E.A., Valkenburg - van Iersel Liselot, Vul*

**T17**

**Clinical Validation and Application of Whole Genome Sequencing for Pharmacogenetic Profiling of DPYD to Prevent Fluoropyrimidine-Induced Toxicity**

*van Merendonk Lisanne, Koster Roelof, van den Broek Daan, Monkhorst Kim, Cats Annemieke, Huitema Alwin, Jacobs Bart*

**T18**

**Discovering novel germline genetic variants outside and inside DPYD associated with the onset of severe fluoropyrimidine-related toxicity**

*Knikman Jonathan E., Zhai Qinglian, Lunenburg Carin A.T.C., Henricks Linda M., van der Lee Maaïke, Böhringer Stefan, de Man Femke M., Offer Steven M., Shrestha Shikshya, Creemers Geert-Jan, Baars Arnold, Dezentje Vincent O., Imholz Alexander L. T., Jeurissen Frank J.*

**T19**

**Survival outcomes after UGT1A1 genotype-guided dosing of irinotecan: results of a multicentre survival analysis**

*Peeters Sofia Lucía Jacinta, Heersche Niels, Böhm Doortje M. M., Böhringer Stefan, Guiljam Roselien, Joosse Marije, Osman Aisha, Hulshof Emma C., de Man Femke M., de With Mirjam, van Hellemond Irene E.G., Haberkorn Brigitte C.M., Verschoor Arjan J., Wumkes Miriam L.*

**T20**

**'Can genetics tame the Red Devil?' Pharmacogenomic testing for anthracycline cardiotoxicity in childhood cancer: A systematic review and meta-analysis**

*Wong Ling Yin Fritz, Sutcliffe Alastair, Ho Carmen Lok Tung, Lu Yan, Williams Carrie, Afzal Faiza, Purkayastha Mitana*

**T21**

**Toxicity outcomes of patients who received UGT1A1 genotype-guided irinotecan dosing: a multicentre real-world study**

Heersche Niels, Peeters Sofia, Bohm Doortje, Böhringer Stefan, Guiljam Roselien, Oomens Gysella, Wu Qiong-Yi, Hulshof Emma, de Man Femke, Bins Sander, van Hellemond Irene, Haberkorn Brigitte, Verschoor Arjan, Wumkes Miriam, van Schaik Ron, Thijs Anna, Gelderblom Hans, Guc

**T22**

**Hydrogel System for Cancer Biomarker Detection**

Saputri Rosalina Intan, Lowry Deborah, Abuelhana Ahmed, Rogers Aoife, Mensah Adelaide, Courtenay Aaron

**T23**

**RTK-KRAS Pathway Alterations and Gender-Related Differences in Locally Advanced Rectal Cancer: Prognostic and Predictive Implications for a Personalized Clinical Model**

Milan Noemi, De Mattia Elena, Scarabel Lucia, Giacomini Aurora, Navarria Federico, Innocente Roberto, Gigante Marco, Ongaro Elena, Cannizzaro Renato, Canzonieri Vincenzo, Belluco Claudio, Montico Marcella, Cecchin Erika

**T24**

**Pharmacogenomics predictors of anthracycline induced cardiotoxicity in Breast cancer patients: a systematic review and meta-analysis**

Bulusu Vani Mahathi, Shah Bhushan, Sawant Sheela, Choudary Akansha, Das Saikat, Jain Suruchi, Singh Jitendra, Arya Neha, Kanwar Rupinder Kaur, Rao Mahadev, Mallayasamy Surulivel Rajan, Udupa Karthik S, Sekaran Mangaiyarkarasi, Kumar Amit, Shinde Ashish, Munisamy Murali

**T25**

**Pharmacogenetics of Multidrug Resistance Protein MRP2 (3972C>T) gene polymorphism with glioma patients receiving Temozolomide based chemoradiation therapy in Indian population**

Munisamy Murali, Munisamy Srinivasan, Kumar Julka Pramod, Kumar Amit, Subbiah Vivekanandhan

**T26**

**Physiologically-based pharmacokinetic modeling of 5-fluorouracil and capecitabine**

Rosenqvist Julia, Filppula Anne M., Kurkela Mika, Hosio Antti, Niemi Mikko

**T27**

**Investigation of driver mutations jak2, calr, and mpl in ukrainian patients with myeloproliferative disorders in the period of full-scale russian-ukrainian war since 2022**

Shurko Nataliya, Maslyak Zvenyslava, Vroniak Myroslav, Khudzij Sofiia, Kokoruz Maryana, Milyashkevych Svitlana

**T28**

**Benefits of next-generation sequencing for the analysis of dihydropyrimidine dehydrogenase deficiency**

*Sourdioux Maxime, Chastagner Dorian, Picard Nicolas*

**T29**

**Genetic variants associated with fluoropyrimidines -related toxicity in colorectal cancer patients: A pharmacogenetic analysis.**

*González-Oter María, Sanz-Solas Antonio, Alcaraz Raquel, Pérez-Gómez Noelia, Vinuesa Raquel, García-Sancha Natalia, López- Muñoz Ana María, Llorente-Ayala Beatriz, López-Peraita Sandra, Medrano-Rodríguez Celia, Saiz-Rodríguez Miriam*

**T30**

**GSTs Variants and Ancestry as Predictors of Gastrointestinal Adverse Events in Ovarian Cancer Chemotherapy**

*Moriel Patricia, Fernanda Santos Fidelis Giovana, Godoy Torso Nadine, Tiemi Siguemoto Julia, Gabriele Matos Yasmim, Preiato de Grande Laura, Carolina Eloy Marcio Ana, Françoise Mauricette Derchain Sophie, Lourenço de Castro Clarissa, Carlos da Costa Junior Luiz*

**T31**

**Pharmacogenetic evaluation in Tunisian chronic myeloid leukemia patients with TKI resistance**

*Frikha Rim, Kamoun Hassen*

**T32**

**Investigating Thyroid Cancer Risk using Polygenic Risk Scores in a Korean Population**

*Park Kyoung-Jin, Park Jong-Ho Park, Jang Woori*

**T33**

**Prevalence of the four mandatory DPYD gene variants in the Lleida healthcare region, Catalonia, Spain.**

*Muñoz Santa Alba, Alonso Llorente Alba, Morell Mesa Guillem, López Ortega Ricard, Ibarz Escuer Mercedes*

**T34**

**When one-dose-doesn't-fit-all: sex and age contribution to imatinib exposure in patients with GIST**

*Gagno Sara, Buonadonna Angela, Posocco Bianca, Cecchin Eleonora, Pasin Diletta, Cecchin Riccardo, Fumagalli Arianna, Montico Marcella, Guardascione Michela, Puglisi Fabio, Cecchin Erika*

**T35**

**Associations of ABCB1 Gene Variants and Genetic Ancestries with Adverse Reactions in Patients with Gynecological Tumors Treated with Paclitaxel and Carboplatin**

*de Godoy Torso Nadine, Fernanda Santos Fidelis Giovana, Tiemi Siguemoto Julia, Gabriele Matos Yasmim, Camargo Lepore Julia, Luchesi Canizares Carolina, Lourenço de Castro Clarissa, da Costa Junior Luiz Carlos, Caleb Júnior Lima Santos Paulo, C. Pincinato Eder, Mo*

**T36**

**Pharmacogenomic panel testing in patients being treated for solid tumours: A Scoping Review**

*Keen Jessica, Shi Chunhu, Braun Michael, Newman William G*

**T37**

**Pharmacogenetic insights into fluoropyrimidine toxicity: Expanding the spectrum of DPYD and related variants**

*Salvador-Martín Sara, Rodríguez María, Rojas Mariam Stephanie, Bravo Adrián, Judit Julian Pena, Maurel Joan, Brunet Serra Mercè, López-Fernández Luis Andrés*

**T38**

**Local skin reactions due to topical 5-fluorouracil treatment: does DPYD-genotype matter?**

*Heersche Niels, de With Mirjam, Oomen-de Hoop Esther, Meier Stijn F A, Verhaar Femke S, Matic Maja, Noz Käthe C, Brinkhuizen Tjinta, van Schaik Ron H N, Mathijssen Ron H J, Deenen Maarten J, Wakkee Marlies, Koolen Stijn L W*

**T39**

**Association of a Common Germline Variation in CD274 (PD-L1) with Overall Survival in Patients with NSCLC Receiving Immune Checkpoint Inhibitors**

*Leijtens Tommy R, Heersche Niels, Uyl Tom J J, van der Leest Cor H, Hofman Maaïke M, de Jonge Evert, Veerman G D Marijn, Oomen-de Hoop Esther, Joerger Markus, Dumoulin Daphne W, van Schaik Ron H N, Aerts Joachim G J V, Coenen Marieke J H, Mathijssen Ron H J*

**T40**

**Improving genotype-phenotype concordance in tamoxifen-treated patients through NGS (Next Generation Sequencing)-based CYP2D6 sequencing**

*PETIT Jeanne, PLENECASSAGNES Julien, BRICE Aurelie, MALLET Ludovic, AL SAATI Ayman, THOMAS Fabienne*

**T41**

**Development of a high throughput, broadly inclusive qPCR genotyping assay to detect AMP Tier 1 variants directly from EDTA whole blood**

*Gasior Anna, Law Daria, Paveley Jack, Pounce Zoe, Byers Helen, McDermott John, Newman William, Coles Amy*

**T42**

**Dihydropyrimidine Dehydrogenase Variant c.257C>T and 5-fluorouracil Toxicity: More Prevalent and Harmful than Expected**

*Efrati Edna, Ring Gil, Shempliner Alexandra, Waldhorn Ithai, Passhak Maria, Shentzer Talia, Mayo Ami, Kurnik Daniel, Carp Marie-Jeanne*

**T43**

**Dihydropyrimidine Dehydrogenase Variant c.496A>G is Strongly Associated with 5-fluorouracil Toxicity**

*Shempliner Alexandra, Carp Marie-Jeanne, Ring Gil, Waldhorn Ithai, Passhak Maria, Shentzer Talia, Kurnik Daniel, Efrati Edna*

**T44**

**Prognostic Genes Revealed by Targeted Panel Sequencing of Pharmacogenes and Oncodrivens in Colorectal Cancer Pat**

*Heczko Lucie, Liška Václav, Vyčítal Ondřej, Fiala Ondřej, Šůsová Simona, Souček Pavel, Hlaváč Viktor*

**T45**

**Reevaluating the use of DPYD c.1236G>A as a proxy marker for HapB3: A cohort study in a Spanish population**

*Álvarez-Montero Miguel, Duenas-Lopez Fiorela, Pardo-Puras Ramón, Diago-Sempere Elena, Arias Pedro, Ferrer Martinez Belén, Rosas-Alonso Rocío, Borobia Alberto M*

**CARDIOLOGY**

**T46**

**Pharmacogenetic Testing in Romania: A Descriptive Analysis of Results and Implementation Challenges**

*Pop Cristina, Curici Antoanela, Vostinaru Oliviu, Mester Andra, Silaghi Alina, Silaghi Horatiu, Apan Anamaria, Mogosan Cristina*

**T47**

**AP-PriME: clinical trial to evaluate the usefulness of prospective genotyping in reducing musculoskeletal adverse events in statin treatment**

*González-Iglesias Eva, Rabadán-Ungo Carmen, Seguido Miguel A, Novalbos Jesús, Lovell-Gaspari Edgardo R, Almenara Susana, Izquierdo-Palomares Jose M, Abad-Santos Francisco*

**T48**

**Pharmacogenetic characteristics of indirect anticoagulant use in cardiac surgery patients in Kazakhstan**

*Svyatova Gulnara, Murtazaliyeva Alexandra, Berezina Galina, Miyerbekov Yergali, Tuletayev Rustam, Nurbay Zhanar, Imammyrzayev Ualikhan, Eset Meruert*

**T49**

**Pharmacogenetic Aspects of Anticoagulant Therapy Following Cardiac Surgery in Patients with VKORC1 1639G>A and CYP2C9\*2&\*3 Genetic Polymorphisms**

*Velizarova Milena, Abedinov Philip, Svinarov Dobrin, Hristova Julieta*

**T50**

**Pharmacometabolomics of Treatment Response to Antihypertensive Drugs – A Systematic Review**

*Knikman Jonathan E., Borzeshi Elahe Z., Valdez Merys, Kindt Alida S. D., Arsi Banafsheh, Memarian Elham, Hankemeier Thomas, Kotecha Dipak, Grobbee Diederik E.*

**T51**

**Association of ABCB1 gene single nucleotide polymorphisms (SNPs) at positions C3435T and G2677T/A with digoxin serum concentrations among Iranian patients under digoxin treatment**

*Kasaei Bahar*

**T52**

**Pharmacometabolomics Detects Various Unreported Metoprolol Metabolites in Urine of (Potential) Living Kidney Donors and Kidney Transplant Recipients**

*Heddema Wietske, Hof Marieke, Sosnowski Piotr, Bakker Stephan, Hopfgartner Gérard, Klont Frank*

**T53**

**Non-targeted metabolomics for the identification of plasma metabolites associated with breast cancer resistance protein function**

*Hämäläinen Kreetta, Deng Feng, Hirvensalo Päivi, Lehtonen Marko, Niemi Mikko*

**T54**

**Actionable Pharmacogenetic Drug Use among Adults using Cardiovascular Disease Drugs in the Netherlands: A Serial Cross-sectional study**

*Zhang Zhuolin, Klont Frank, Zhou Guiling, Bos Jens, Hak Eelko, Feenstra Talitha*

**T55**

**Genetic variation in *ptgs1* and risk of upper gastrointestinal bleeding: a case-control study in Brazil**

*Forgerini Marcela, Nadai Tales Rubens de, Urbano Gustavo, Mastroianni Patrícia de Carvalho*

**T56**

**Optimising Dual Antiplatelet Therapy in Acute Coronary Syndrome Patients Undergoing Percutaneous Coronary Intervention: Cost-Effectiveness Analysis of Genotype-Guided Treatment in England**

*Mahboub-Ahari Alireza, Rodrigues Maria, Hilton Joe, McDermott John H, Newman William G, Payne Katherine*

**T57**

**Pharmacogenomics for Long-Term Atorvastatin Treatment in Acute Coronary Syndrome Patients**

*Čereškevičius Darius, Čiapienė Ieva, Tatarūnas Vacis*

**T58**

**Clopidogrel metabolism is not affected by the CYP2C: TG haplotype**

*Coenen Marieke, Struik Misha, Wijnen Petal, Olie Renske, Bekers Otto, van Schaik Ron, Henskens Yvonne*

**T59**

**CYP1A2\*30 Polymorphism Is Associated with Hepatobiliary Dysfunction in Chronic Heart Failure Patients**

*Doka Gabriel, Krajcirova Natalia, Stollarova Natalia, Krenek Peter, Kilianova Zuzana, Klimas Jan*

### **T60**

#### **CYP450 Pharmacogenetic Variability and Its Impact on the Intensity of Hypotensive Pharmacotherapy in Chronic Heart Failure**

*Krajcirova Natalia, Stollarova Natalia, Krenek Peter, Kilianova Zuzana, Klimas Jan, Doka Gabriel*

### **T61**

#### **Pharmacogenomic Risk Profiling of Statin Response in Portuguese Familial Hypercholesterolemia and General Population Cohorts**

*Chora Joana Rita, Grade M. Mafalda, Antunes Marília, Bourbon Mafalda*

### **T62**

#### **Pharmacogenetics of direct oral anticoagulants: rivaroxaban and apixaban associated bleeding in patients treated for atrial fibrillation and venous thromboembolism**

*Palić Jozefina, Slišković Ana Marija, Šimičević Livija, Ganoci Lana, Pašara Vedran, Samardžić Jure, Bulum Joško, Lovrić-Benčić Martina, Božina Tamara*

### **T63**

#### **Drug-drug-gene interactions in predicting cardiovascular drug-related efficacy and safety outcomes - PGx-CardioDrug Project**

*Ganoci Lana, Šimičević Livija, Palić Jozefina, Slišković Ana Marija, Vrkić-Kirhmajer Majda, Mucalo Iva, Bičanić Lucija Ana, Karačić Ena, Pašara Vedran, Starčević Katarina, Leskovar Lemešić Dunja, Pećin Ivan, Božina Nada, Trkulja Vladimir, Božina Tamara*

### **T64**

#### **Medication Use and Cardiovascular Risk in Portugal: A Population-Based Study with Pharmacogenomic Perspectives**

*Oliveira Nayara Damacena, Alves Ana Catarina, Cardoso Maria Luís, Garvão Filipa Alexandra Nobre, Grade Maria Mafalda, Bourbon Mafalda*

### **T65**

#### **Pharmacogenetic Determinants of Bleeding Risk and Drug Response in Patients Treated with Direct Oral Anticoagulants**

*Rochmawati Ike Dhiah, Anggriawan I Made Bayu, Pell Jill, Welsh Paul, Ho Frederick, Morales Carlos-cellis*

## **SOLID ORGAN TRANSPLANTATION**

### **T66**

#### **Dose, kidney function, and a drug-exciipient interaction impair mycophenolate mofetil prodrug activation in kidney transplant recipients**

*Nijdam Fleur, Hof Marieke, Kremer Daan, Knobbe Tim, Hopfgartner Gérard, Hak Eelko, Bakker Stephan, Klont Frank, Investigators TransplantLines*

### **T67**

#### **Challenges in tacrolimus dosing under standard care in paediatric solid organ transplantation**

*Netylko Julia, Khatri Dhrita, Halman Andreas, Metz David, Conyers Rachel*

**T68**

**Lower Dose-Normalized Tacrolimus Exposure in CYP3A5\*6 vs.\*3 Loss-of-Function Allele Carriers: A Longitudinal Retrospective Real-World Study in Kidney Transplant Recipients**

*Levens Amar, Moes Dirk Jan, Boer Yanick, De Vries Aiko, De Vries Dorottya, Van der Helm Danny, Meziyerh Soufian, Roelen Dave, Böhringer Stefan, Van Gelder Teun, Swen Jesse*

**T69**

**Structural modeling reveals the critical role of binding peptides in HLA-B\*57:01 associated drug hypersensitivity reactions**

*Zhong Yi, Lauschke Volker, Zhou Yitian*

**T70**

**Association between angiotensin-converting enzyme gene polymorphisms and clinical outcomes in kidney transplant patients**

*Jevtic Nenad*

**T71**

**REtrospective analysis of the inFLuence of antibiotic treatments on the pharmacokinEtics of taCrolimus in kidney Transplant patients (REFLECT study)**

*Barbé Alice, Bindels Laure B., Van Bambeke Françoise, Devresse Arnaud, Elens Laure*

**T72**

**Impact of Pharmacogenetic Variants on the Long-Term Clinical Course of Kidney Transplant Patients**

*Sendra Luis, Olivera-Pasquini Gladys G., Zucchet Enrique G., Genvigir Fabiana DV, Beneyto María Isabel, Hernández-Jaras Julio, Herrero María José, Aliño Salvador F.*

**T73**

**A Bayesian Network Approach to Exploring Pharmacogenetic and Clinical Factors Associated with Tacrolimus Clearance in Paediatric Kidney Transplant Recipients**

*Guzmán de Antonio Andrea, Díaz García Lucía, Zarauza Santoveña Alejandro, Morante Martínez Diego, Leiva Castrejón Leyder Larry, Borobia Pérez Alberto M., Carcas Sansuán Antonio J.*

**T74**

**Effect of lactic acid bacilli on the immunosuppressant drugs mycophenolic acid, mycophenolate mophetyl, and mycophenolic acid 7-o-glucuronide: pharmacomicrobiomic implications**

*Di Renzo Tiziana, Reale Anna, Di Giacomo Annamaria, Spagnuolo Carmela, Cataldi Mauro*



## DIABETES

**T75**

### **Genomic Insights into Oxidative Stress: Novel Biomarkers for Type 2 Diabetes Mellitus**

*Gusti Amani*

**T76**

### **Assessment of Glycemic Control Influence on Platelet Function**

*Katar Muzaffer*

**T77**

### **Partitioned polygenic scores and response to GLP-1 receptor agonist therapy in diabetic patients from randomized controlled trials**

*Pilon Marc-Olivier, de Denus Simon, Barhdadi Amina, Dawed Adem Yusuf, Haider Eram, Asselin Géraldine, Lemieux Perreault Louis-Philippe, Mongrain Ian, Palmer Colin, Paul Dirk S, Tardif Jean-Claude, Pearson Ewan, Dubé Marie-Pierre*

**T78**

### **Genetic variation of SLCO1 and CYP2C8 have a major effect on repaglinide pharmacokinetics**

*Mykkänen Anssi, Hirvensalo Päivi, Klein Kathrin, Kaminska Dorota, Grube Markus, Tapaninen Tuija, Kiiski Johanna, Neuvonen Mikko, Männistö Ville, Pihlajamäki Jussi, Tzvetkov Mladen, Schwab Matthias, Backman Janne, Tornio Aleks, Niemi Mikko*

## NATIONAL SOCIETY INITIATIVES

**T79**

### **The genomDE Model Project - implementation of personalized medicine in patient care in Germany**

*Scholl Catharina, Hübner Tatjana, Klatt Rudolf, Pötschke Luca, Hänisch Britta, Till Andreas*

**T80**

### **The Italian Roadmap for Germline Pharmacogenomics Implementation in routine diagnostics: From Evidence-Based Analysis to National Recommendations for laboratory practice by the Joint Working Group for the Implementation of Pharmacogenetics in Italy**

*Floris Matteo, Moschella Antonino, Capasso Mario, Nicoletti Paola, Roncato Rossana, Mammi Corrado, Conti Valeria, Filippelli Amelia, Squassina Alessio, Miozzo Monica, Cecchin Erika*

**T81**

### **Unveiling the heritability of selected unexplored pharmacogenetic markers in the Saudi population**

*Alshabeeb Mohammad, Deemah Alwadaani, Sireen Shilbayeh, Fatemah Alherz, Ali Alghubayshi*

## CLINICAL IMPLEMENTATION

### F01

#### **Design of an array to evaluate biomarkers of response to biological treatments in inflammatory bowel disease**

Rodríguez-Lopez Andrea, González-Iglesias Eva, Novalbos Jesús, Almenara Susana, Abad-Santos Francisco

### F02

#### **Genetic Association of Sphingosine 1-Phosphate 1 (S1P1) Polymorphism with Finglomid Efficacy in Jordanian Patients with Multiple Sclerosis**

Hakooz Nancy, Banat Osama, Yazun Jarrar

### F03

#### **Role of pharmacogenetics on tramadol pharmacokinetics: a population pharmacokinetic model.**

Soria-Chacartegui Paula, Würthwein Gudrun, Zubiaur Pablo, Almenara Susana, Ochoa Dolores, Abad-Santos Francisco, Hempel Georg

### F04

#### **Is the measurement of CP levels in clinical routine samples applicable to quantify drug-drug-gene interactions involving OATP1B1?**

Potzel Leila, Zumtaugwald Anina, Allemann Samuel, Meyer zu Schwabedissen Henriette E., Stäuble Céline K.

### F05

#### **Reviewing five years of external quality assessment for DPYD**

Treacy Becky, Hughes Lowri, Cregeen Dave, Deans Zandra

### F06

#### **Validation of pharmcat: a pharmacogenomics tool for whole genome sequencing data to optimize treatment and minimize side effects in pediatric oncology**

Diekstra Meta, Biesot Nienke, Donders Julie, Huitema Alwin, Hanff Lidwien, Tops Bastiaan, Kemmeren Patrick, Hehir-Kwa Jayne

### F07

#### **Warfarin Hyper-Responsiveness in a Female Patient with Deep Venous Thrombosis and CYP2C9\*1\*3 and VKORC1-1639 AA Genotypes**

Aldiban Weam, Altawil Yara, Hussein Samir, Aljamali Majd, Youssef Lama A.

### F08

#### **Mapping Pharmacogenetic Clinical Trials: A Quantitative Exploration of Key Trends**

Ozunal Zeynep Gunes, Akca Oya

**F09**

**Reporting adverse drug events: a comparison of an online patient tool versus telephone-based monitoring in community pharmacy patients in the Netherlands**

*Habtemariam Henok*

**F11**

**Implementing CYP2C19 Pharmacogenetic Testing for Personalized Antiplatelet Therapy: Findings from the QPGx-CARES Initiative**

*Abdel-Ilaf Rania, Al Muftah Wadha, Mohammed Shaban, AlHsson Toka, Al-Badriyeh Daoud, Badji Radja, Al-Qahtani Awad, Arabi Abdul Rahman, Ismail Said, Al Hail Moza, Al Suwaidi Jassim*

**F12**

**Introducing pharmacogenomic guided prescribing in UK general practice: a qualitative process evaluation**

*Brunton Lisa, Newman William, McDermott John, Wilson Paul*

**F13**

**Clinical implementation of CYP2C19 Genotyping testing in a tertiary hospital from Singapore**

*CHEN Eileen Xueqin, Kho Mariana Jiajia, Tan Bryan Giin Chyuan, Narasimhalu Kaavya, Wong Pei Shieen, Chan Kian Sing, Oon Lynette Lin Ean*

**F14**

**Digitalisation and thermoprinting improves screening for CVDs at health facilities in Mukono and Buikwe in Uganda: An implementation Science Study**

*Zewulensi Kayanga*

**F15**

**Hypertension and diabetes patients' perspective of challenges and their coping mechanisms in Mukono and Buikwe districts in Uganda – a qualitative study**

*Zewulensi Kayanga, Ddumba Isaac*

**F16**

**Allele frequency of Association for Molecular Pathology (AMP) Tier 1 and 2 recommended Pharmacogenetic variants in Argentina**

*Farquharson M. Victoria, Bes Elisangela, Bernardi Alejandra, Alonso M. Patricia, Pasqualini Natalia, Aliendro Carolina, Machaca Matias, Da Coceincao Betiana, Maggi Liliana, Franklin Brandon, Pratt Victoria*

**F17**

**Potential Risk of Phenoconversion in the Swiss Population: A Descriptive Study Using Claims Data Focusing on Drugs Metabolized by the Enzymes CYP3A4/5 and CYP2B6 or Transported by OATP1B1 and BCRP**

*Roth Marietta, Bencastro Aline, Meier Christoph R., Huber Carola A., Meyer zu Schwabedissen Henriette E., Allemann Samuel, Schneider Cornelia*

**F18**

**Association of Pharmacogenotyping and Patient-Reported Outcomes in Chronic Pain Management: A Pre-To-Post Analysis**

Bollinger Anna, Hersberger Kurt E, Gianora Julia, Urdieux Isabelle O, Meyer zu Schwabedissen Henriette E, Schwenkglenks Matthias, Rommers Nikki, Stäuble Céline K, Allemann Samuel S

**F19**

**Pharmacogenomic testing for personalised prescribing in primary care: a systematic review of global implementation studies**

Darko Julia, Sekwo Daniel, Routen Ash, Khunti Kamlesh

**F20**

**Verification of the accuracy, precision and sensitivity of the LightSNiP DPYD c.557A>G probe from TIB Molbiol.**

Alonso Llorente Alba, Muñoz Santa Alba, Blanquero Porras Adrián, Morell Mesa Guillem, López Ortega Ricard, Ibarz Escuer Mercedes

**F21**

**Stratified Opportunity for Reactive Pharmacogenomic Testing in Older Adults: A Population-Based Study from a PGx-Naïve Health System**

Lip Stefanie, Tran Tran QB, Padmanabhan Sandosh

**F22**

**Rethinking Pre-emptive Pharmacogenomic Testing in an Ageing Population: Timing, Clinical Burden, and Inequality.**

Lip Stefanie, Tran QB Tran, Padmanabhan Sandosh

**F23**

**Public Preferences for Pharmacogenetic Testing in the NHS: Embedding A Discrete Choice Experiment within Service Design to Better Meet User Needs**

McDermott John, Sharma Videha, Newman William, Wilson Paul, Katherine Payne, Wright Stuart

**F24**

**Genetic ancestry and phenotypes of TPMT and NUDT15 in patients from the Brazilian Unified Health System (SUS)**

Tieme Siguemoto Julia, Godoy Torso Nadine, Fernanda Santos Fidelis Giovana, Eduardo Nascimento Silva Vasconcelos Pedro, Gabriele Matos Yasmim, Augusto Sakae Defende José, Eduardo Castelano da Silva João, Lourenço de Castro Clarissa, Carlos da Costa Junior Luiz, Ca

**F25**

**A proof-of-concept interoperable informatic solution to enable pharmacogenomic-guided prescribing in a secondary care electronic health record in the UK: PROGRESS Rx**

McIntyre Ben, Keen Jessica, McDermott John H, Sharma Videha, Grey Chris, Wren Alex, Dixon Christopher, Steiner Chris, Parkinson Mike, Watson Scott, Newman William G

**F26**

**Pharmacogenomics in pediatric care: a global overview of clinical implementation**

*van Gijzen Merel Willemijn, Masroor Amirhossein, Diekstra Meta H M, te Loo D Maroeska W M, van den Heuvel-Eibrink Marry M, Coenen Marieke J H*

**F27**

**Genotype–Phenotype Guided Personalisation of Azathioprine Therapy in Autoimmune Hepatitis: Real-World Data from Routine Clinical Practice**

*Julian Judit, Olivas Ignasi, Lizana Ana, Hernandez-Evole Helena, Rodríguez-Tajes Sergio, Londoño Maria Carlota, Brunet Mercè*

**F28**

**Northern Ireland Prescribing Practices and Potential Impact of PGx Phenotypes**

*Ali Mohamed, Zhang Shu-Dong, Burns Richeal, Gibson David, Kelly Catriona*

**F29**

**SLCO1B1 and ABCG2 Pharmacogenetic Testing: The way to prevent the adverse effects of statins?**

*Hernaez Mar, Mateu Manel, Garcia Alba, Andrea Rut, Viñals Clara, Ortega Emilio, Brunet Mercè*

**F30**

**Aiding clinical implementation of PGx through appropriate education and training**

*Dumenu Priscilla, McLean Samantha, Silcock Jonathan, Groves Emma, Silcock Helen, Tomlinson Justine*

**F31**

**Population Pharmacogenomics for clinical implementation in Serbia: Insights from the PharmGenHUB Study**

*Jelovac Marina, Pavlovic Djordje, Stankovic Biljana, Kotur Nikola, Ristivojevic Bojan, Pavlovic Sonja, Zukic Branka*

**F32**

**Drug–Gene Interactions in Older Adults: A Prospective Study of Pharmacogenetic Variants and Polypharmacy**

*Estepa Sandra, Erenas Isabel, Chicharro Celia, Velasco Verónica, Sainz María, Ollauri Claudia, Fernandez-Araque Ana M<sup>a</sup>, Verde Zoraida*

**F33**

**Design and validation of a custom array expanding the spanish pharmacogenetic portfolio**

*García González Xandra, López Fernández Luis Andrés, Taladríz Sender Irene, Zapata Cobo Paula, Hernández Osio Gina, Peñaherrera Meybi, Sanjurjo Sáez María, Salvador Martín Sara*

**F34**

**BioFRAM: A National Strategy for Pharmacogenetic Biomarker Integration to Prevent Adverse Drug Reactions in Mental Health and Cardiology. Experience from Galicia**

*Gil-Rodriguez Almudena, Recarey-Rama Sheila, Vidal-Millares María, Torres Ángela J, Ramos-Ríos Ramón, Otero-Lago Nuria, Sempere-Serrano Paloma, Calviño Rita, Caicedo Diego, Barral-Raña Alba, Rodríguez-Viyuela Ana, Páramo Fernández Mario, Arrojo Romero Manuel, Maroñas*

**F35**

**Dutch Pharmacogenetics Working Group (DPWG) Guideline for the Gene-Drug Interaction of CYP2D6 with Antiarrhythmic Drugs including Beta-blockers**

*den Uil Manon G., Wagelaar Kay R., Nijenhuis Marga, de Boer-Veger Nienke J., Buunk Anne Marie, Guchelaar Henk-Jan, Houwink Elisa J.F., Risselada Arne, van Schaik Ron H.N., Rongen Gerard A. P. J. M., Swen Jesse J., Touw Daan J., van Westrhenen Roos, Deneer Vera H. M.*

**F36**

**Distribution of HLA DQ2/DQ8 in Georgia – Single Center Experience**

*Rtskhladze Nino, Rtskhladze Ketevan, Ramishvili Tamar, Rtskhladze Irakli*

**F37**

**Retrospective pharmacogenetic analyses of a dementia cohort**

*Meyer-Tönnies Marleen Julia, Schwarz Leefke, Hoffmann Wolfgang, Thyrian Jochen René, Tzvetkov Mladen*

**F38**

**Implementation of MT-RNR1 m.1555A>G detection kit to reduce aminoglycoside induced hearing loss (AIHL) at the Neonatal Intensive Care Unit (NICU).**

*Boshoven Glenn, Schaik van Ron, Hulskamp Emare, Coenen Marieke, Matic Maja*

**F39**

**Pharmacokinetic recall study of Estonian Biobank participants carrying novel genetic variants in CYP2C19 and CYP2D6**

*Luitva Laura Birgit, Krebs Kristi, Kõre Anette Caroline, Kokasaar Raul, Jõeloo Maarja, Hudjashov Georgi, Maal Kadri, Wollmann Birgit Malene, Størset Elisabet, Karo-Astover Liis, Fischer Krista, Ingelman-Sundberg Magnus, Lauschke Volker M, Molden Espen, Oselin Kersti*

**F40**

**Pharmacogenetics in Primary Care: Identifying and Resolving Drug Therapy Problems Through Comprehensive Medication Management**

*Čuljak Mihaela, Planinić Kristina, Bićanić Lucija Ana, Orehovački Helena, Ganoci Lana, Brajković Andrea, Mucalo Iva*

**F41**

**Implementation of the Spanish Pharmacogenetic Portfolio in a Tertiary Hospital: a Retrospective Analysis of the First Year.**

*Pardo Puras Ramon, García Lopez Abraham, Álvarez Montero Miguel, Diago-Sempere Elena, Arias Pedro, Ferrer Martínez Belen, Rosas-Alonso Rocío, Borobia Alberto Manuel*

**F42**

**Tier 1 DPYD variants frequency in a Brazilian cohort**

*Carvalho Pincinato Eder, Aguiar Zollmann Luciana, Fernanda Santos Fidelis Giovana, Godoy Torso Nadine, Tiemi Siguemoto Julia, Gabriele Matos Yasmim, Carolina Eloy Marcio Ana, Françoise Mauricette Derchain Sophie, Lourenço de Castro Clarissa, Carlos da Costa Junior*

**F43**

**Perceptions of hospital physicians on barriers and facilitators related to the implementation of pharmacogenetics**

*Steurbaut Stephane, Janssens Anne-Sophie, Cortoos Pieter-Jan*

**F44**

**Pilot Implementation of the Pharmacogenetic Passport: A Lifelines Cohort Study on Uptake, Attitudes, and Preferences**

*Westervoorde Suze Elisa, Christiaans Imke, Dekens Jackie A. M., Slager Jelle, Plantinga Mirjam, Ranchor Adelita V.*

**F45**

**Barriers and facilitators for implementing a pharmacogenetic passport: lessons learned from reusing sequencing data**

*Roelofsen Anja, Kreeftenberg Loes Lindiwe, van El Carla, Henneman Lidewij, Rigter Tessel, Sie Daoud, Bet Pierre, Cornel Martina*

**F46**

**Current Landscape of Pharmacogenetic Testing in Europe: Insights from EACPT Member Country Survey**

*Kulla Noora, Litonius Kaisa, Javid Farideh, Potočnjak Ines, Stanić BeniĆ Mirjana, Roncato Rossana, Aurinsalo Laura, Belančić Andrej*

**LIQUID BIOPSY**

**F47**

**Identification of endogenous substrates of ABC transporters using untargeted metabolomics**

*Deng Feng, Lehtonen Marko, Kurkela Mika, Neuvonen Mikko, Niemi Mikko*

**F48**

**Monitoring circulating tumor DNA levels as a prognostic tool to predict pathological response and relapse in Locally Advanced Rectal Cancer patients**

*Giacomin Aurora, Milan Noemi, De Mattia Elena, Scarabel Lucia, Ongaro Elena, Navarra Federico, Innocente Roberto, Gigante Marco, Belluco Claudio, Cecchin Erika*

**F49**

**A Method for Detection of EGFR T790M Mutations for Liquid Biopsy in Non-Small Cell Lung Cancer Patients**

*Mahadev Rao, Baburaj Gayathri, Parida Preetiparna, Pai Ananth, Damerla Rama Rao, Udupa Karthik*

**F50**

**Liquid biopsy biomarkers for personalized post-transplant care: Clinical relevance of dd-cfDNA and microRNA monitoring in liver transplantation**

*Julian Judit, Millan Olga, Ruiz Pablo, Titos Esther, Diaz Alba, Colmenero Jordi, Fundora Yiliam, Fondevila Constantino, Puig-Butille Joan Anton, Brunet Mercè*

**DECISION SUPPORT TOOLS**

**F51**

**Solanidine analysis during therapeutic drug monitoring revealed rare CYP2D6 poor metabolizer genotype: a case report**

*Wollmann Birgit M., Størset Elisabet, Larne Sverre Gunnarsson, Bråten Line Skute, Kringen Marianne Kristiansen, Molden Espen*

**F52**

**Relapse rate after withdrawal of anti-TNF therapy in patients with IBD in deep remission**

*Molin Daniel, Haglund Sofie, Hedin Charlotte, Hjortswang Henrik, Hertervig Erik, Almer Sven, Marsal Jan*

**F53**

**A Model-Informed Algorithm for Personalized Infliximab Rescue Therapy to Maximize Colectomy-Free Survival in Patients with Acute Severe Ulcerative Colitis**

*Niyigena Emmanuel, Hoffert Yannick, Peyrin-Biroulet Laurent, Afif Waqqas, Pedicelli Alessandro, Roblin Xavier, Hanžel Jurij, Papamichael Konstantinos, Kobayashi Taku, Wang Zhigang, Verstockt Bram, Vermeire Séverine, Vande Casteele Niels, Battat Robert*

**F54**

**'PGx ExploreEZ' A Web-Based User-Friendly Tool for Exploration of Pharmacogenomics Reference Resources**

*Hamama Rasha*

**F55**

**An Optimized Data Analysis Pipeline for Pharmacogenomics: Nextflow Implementation**

*van der Maas Sven*

**F56**

**Influence of CYP450 enzymes phenotypes in the occurrence of mental health adverse events related to antidepressant and antipsychotic treatment in Huntington's Disease**

*Pérez-Gómez Noelia, Sanz-Solas Antonio, Koller Dora, Simón-Vicente Lucía, Rivadeneyra-Posadas Jéssica, Aguado Laura, Muñoz Siscart Ignacio, Diaz Piñeiro Dolores, Miguel-Pérez Irene, Trillo Patricia, Mariscal Natividad, Cubo Esther, Saiz-Rodríguez Miriam*



**F57**

**Oxytocin Receptor Gene Polymorphisms and Their Influence on Motor symptoms and Social Cognition in Huntington's Disease: Results from the ENROLL-HD Dataset**

*García-Sancha Natalia, Saiz-Rodríguez Miriam, Koller Dora, Barbero-Aparicio José Antonio, Díez-Pastor José Francisco, Simón-Vicente Lucía, Rivadeneyra-Posadas Jéssica, García-Bustillo Álvaro, Aguado Laura, Muñoz-Siscart Ignacio, Diaz-Piñeiro Dolores, Miguel-Pérez Ir*

**GENOTYPING TECHNOLOGY**

**F58**

**A Novel PCR Assay Reveals Undetected CYP2D6\*13 hybrid Variants and Improves Phenotypic Classification**

*Bråten Line S, Kausberg Marianne, Wollmann Birgit M. T., Kringen Marianne Kristiansen*

**F59**

**Pharmacogenetic testing – Can oral mucosa be used for long read sequencing with Oxford Nanopore technologies?**

*Glässner Andreas, Steffens Michael, Darm Paula, Hahn Martina, Scholl Catharina*

**F60**

**Direct comparison of Oxford Nanopore Technologies adaptive sampling with the Twist Alliance long-read hybridization panel for pharmacogenomic passport construction**

*Deserranno Koen, Tilleman Laurentijn, Deforce Dieter, Van Nieuwerburgh Filip*

**F61**

**Development and Validation of a Comprehensive Gene Targeted Short Read NGS-Based Pharmacogenetic Test Panel for Personalized Medicine**

*Lindqvist Appell Malin, Green Anna, Fredriksson Nils Johan, Andresen Michael, Jonasson Jon, Green Henrik*

**F62**

**Simultaneous detection of SNVs and structural variation in pharmacogenes using a targeted digitalMLPA assay**

*Landsberger Mariann, Alves Beatriz, van Vught Paul, Vijzelaar Raymon, Schouten Jan*

**F63**

**Characterisation of SNVs and structural variants of CYP2D6 using a single digitalMLPA assay**

*Landsberger Mariann, Alves Beatriz, van Vught Paul, Vijzelaar Raymon, Schouten Jan*

**F64**

**Axiom™ PharmacoPro™: Enhanced Coverage and Rapid Turnaround for Comprehensive Pharmacogenomic Analysis**

*Bruckner Carsten, Garg Neha, Varma Ram*

**F65**

**Simultaneous Profiling of SNP Genotyping, Copy Number Variation and Fragment Length Determination Using Nanofluidic qPCR for Pharmacogenomics Studies**

*Ramalingam Naveen, King David, Park Charles, Alipaz Julie, Goralski Tom, Harris Greg, Barican Arnaldo, Brockman Joel, Hui Ren, Jian Qin, Khanna Amit, Hwang Win*

**F66**

**Improved Pharmacogenetic Profiling Through Next Generation Sequencing: A Comparative Case Analysis**

*Garcia Beatriz, Argente del Castillo Paula, Torres Laura, Puiguriquer Jordi, Asensio Victor, Bauçà Josep Miquel, Llompart Isabel*

**F67**

**Evaluation of a Pharmacogenomic Panel Combining SNP and Copy Number Variation Detection for Drug Metabolism Gene Phenotyping**

*Feenstra Jelena, Hayashibara Kathleen, Brzoska Pius*

**F68**

**Performance evaluation of an advanced pharmacogenetic panel testing approach combining SNP and copy number variants detection in a single workflow**

*Hernandez Osio Gina, Garcia Ortiz Maria Jesus, Hayashibara Kathleen, Feenstra Jelena, Lopez Fernandez Luis*

**F69**

**Assessment of a Combined SNP and CNV Pharmacogenomics Panel Using Buccal and Blood Samples**

*Feenstra Jelena, Wong Grace, Chua Cui Wen, Xu Xiaohan, Letchmanan Shamala, Chia Sing Yi, Hayashibara Kathleen, Kong Say Li*

**F70**

**Pharmacogenetic predictors of bortezomib-induced toxicity in multiple myeloma patients: a multi-center study**

*SANZ SOLAS ANTONIO, Pérez Gómez Noelia, González Oter María, García Sancha Natalia, Díaz-Gálvez Francisco Javier, Cuevas Beatriz, Cuevas Maria Victoria, Álvarez-Nuño Rodolfo, Alonso-Madrigal Cristina, Benzo Gonzalo, Rodríguez-López Andrea, Labrador Jorge, Navare*

**F71**

**Genetic ancestry and CYP2D6 phenotypes in patients from the Brazilian Unified Health System (SUS)**

*Siguemoto Julia T., Torso Nadine Godoy, Fidelis Giovana Fernanda, Vasconcelos Pedro Eduardo Nascimento Silva, Matos Yasmim Gabriele, Defende José Augusto Sakae, da Silva João Eduardo Castelano, de Castro Clarissa Lourenço, Junior Luiz Carlos da Costa, Santos Paulo*

**F72**

**Assessment of the X9 Genotyping System for High-Throughput Pharmacogenetic Testing in a Diagnostic Laboratory**

*Camps Bregje, Matic Maja, Boshoven Glenn, Coenen Marieke JH, Schaik Ron HN*

**F73**

**Compound heterozygous DPYD and UGT1A1\*28/\*93 CIS/TRANS analysis using ddPCR**  
*de Jonge Evert, Matic Maja, Coenen Marieke, Heersche Niels, del Re Marzia, van Schaik Ron*

**F74**

**Using third generation sequencing to analyse 51 pharmacogenetic genes in twenty-four clinical samples in one test**  
*Herbers Eva, van Breemen Stef, Eiloz Dafna*

**F75**

**Saliva collection method for pharmacogenetic testing**  
*Kreuger Anouk, Filmer Ilse, van Erp Sarah*

## **REGULATORY ASPECTS**

**F76**

**Development of external quality assessment for aminoglycoside ototoxicity pharmacogenomic testing.**  
*Cregeen David, McCarthy Emma, Treacy Becky, Deans Zandra*

**F77**

**Mechanisms of phantom pain (clinical case report)**  
*Kuznetsova Milena, Kuznetsova Irena, Bibichenko Viktoriia, Kuznesov Kostiantyn, Matsuha Darya, Karelin Maksym, Anosova Viktoriya*

**F78**

**A mathematical decision-analytical model of the cost-effectiveness of implementing a nationwide pharmacogenetic (PGx-)panel test in the Netherlands from a societal perspective.**  
*Hu Jacky, Rutten-van Mölken Maureen, Swen Jesse*

## **PRECISION MEDICINE AND PERSONALIZED HEALTH**

**F79**

**A national pilot of reactive laboratory testing for CYP2C19 to guide antiplatelet use after ischaemic stroke or transient ischaemic attack**  
*Monk Thomas, Stinton Victoria, Howard Emma, Newman William, McDermott John, Sharma Videha*

**F80**

**Gestational weight gain and postpartum weight retention: what is the role of perinatal antidepressant use?**  
*van Wijk Emma, Zugic Milica, Rostami Sina, van Gelder Marleen, Ahmad Ashi Sarfraz, Sitras Vasilis, Spigset Olav, Lupattelli Angela, Trinh Nhung*

# SPONSORS

## ● Diamond ●



## ● Platinum ●



## ● Gold ●



## ● Silver ●



## ● Bronze ●





European Society of Pharmacogenomics  
and Personalised Therapy  
[www.esptsociety.eu](http://www.esptsociety.eu)

[www.esptcongress.org](http://www.esptcongress.org)

**rotterdam  
partners**

**ROTTERDAM ←  
COLLABORATION  
→ FOR CHANGE**

Organising Secretariat  
**MZ Events**  
T. +39 0266802323  
[info@esptcongress.org](mailto:info@esptcongress.org)

